Drug Type Small molecule drug |
Synonyms LPA1R antagonist - Epigen Biosciences/Novo Nordisk, EPGN 696, EPGN-696 |
Target |
Mechanism LPAR1 antagonists(Lysophosphatidic acid receptor Edg-2 antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Idiopathic Pulmonary Fibrosis | Preclinical | US | 01 May 2020 | |
Nonalcoholic Steatohepatitis | Preclinical | US | 24 May 2018 | |
Diabetic Nephropathies | Preclinical | US | - | |
Diabetic Nephropathies | Preclinical | US | - |